Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer

ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism

(2019) David H. Peng et al.   Science Translational Medicine

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

(2018) Ferdinandos Skoulidis et al.   Cancer Discovery

CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade

(2018) Limo Chen et al.   Cancer Discovery

Identification of essential genes for cancer immunotherapy

(2017) Shashank J. Patel et al.   NATURE

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

(2017) Robert T. Manguso et al.   NATURE

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

(2016) Willy Hugo et al.   CELL

Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment

(2016) Stefani Spranger   INTERNATIONAL IMMUNOLOGY

PD-1 says goodbye, TIM-3 says hello

(2016) Diana Romero   Nature Reviews Clinical Oncology

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

(2016) Jesse M. Zaretsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

ZEB1 induces LOXL2-mediated collagen stabilization and deposition in the extracellular matrix to drive lung cancer invasion and metastasis

(2016) D H Peng et al.   ONCOGENE

Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer

(2016) Ruth J. Davis et al.   ORAL ONCOLOGY

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints

(2016) Shohei Koyama et al.   Nature Communications

Tracking Down Response and Resistance to TRK Inhibitors

(2016) R. A. Okimoto et al.   Cancer Discovery

In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer

(2016) Alessandro Carugo et al.   Cell Reports

The microRNA-200/Zeb1 axis regulates ECM-dependent β1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL

(2016) Christin Ungewiss et al.   Scientific Reports

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer

(2015) Anna F. Farago et al.   Journal of Thoracic Oncology

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

TRK Inhibitor Shows Early Promise

(2015)   Cancer Discovery

Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

(2015) F. Skoulidis et al.   Cancer Discovery

Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells

(2015) Annie A Wu et al.   OncoImmunology

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

(2014) Limo Chen et al.   Nature Communications

Immune Modulation in Cancer with Antibodies

(2013) David B. Page et al.   Annual Review of Medicine

Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer

(2013) Aria Vaishnavi et al.   NATURE MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Suppression of lung adenocarcinoma progression by Nkx2-1

(2011) Monte M. Winslow et al.   NATURE

Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression

(2009) D. L. Gibbons et al.   GENES & DEVELOPMENT

Expression Signatures of Metastatic Capacity in a Genetic Mouse Model of Lung Adenocarcinoma

(2009) Don L. Gibbons et al.   PLoS One

PD-1 and Its Ligands in Tolerance and Immunity

(2008) Mary E. Keir et al.   Annual Review of Immunology